Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dendreon up on Provenge SPA

DNDN was up $1.34 (20%) to $8.19 on 7.4 million shares on Wednesday on news that it received a Special

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE